August 2016: Invested in a future of #NoHep in Australasia? We urge you to join a multi-disciplinary delegation at the Australasian Viral Hepatitis Conference (29 Sept – 1 Oct 2016, Gold Coast). The registration closing date to join closes soon on 18 September.
In one of the most important years in Australasian viral hepatitis, there will never be a moment like this in our field again–exciting times for patients, carers and professionals alike. We are at a unique moment in history to reduce the burden of HCV in Australia and New Zealand. The multi-disciplinary nature of the conference ensures that all in the sector will gain valuable information and networking opportunities from attending. Take advantage of an excellent training and continuing medical education (CME) opportunity that the conference provides.
Have a Twitter account?
You can also follow the of-the-moment live feeds from the conference and join in on the dialogue via @ASHMMedia with the conference hashtag #VH16
Program Overview Available
Keep updated by visiting the conference website as we update with more information on the program and invited speakers and as it becomes available.
Scroll down below and read through some of the selected speakers and program highlights that shouldn't be missed:
Keynote speaker, Peter Revill (Senior Medical Scientist, Victorian Infectious Diseases Reference Laboratory of Doherty Institute) presents Global Strategies are Required to Cure and Eliminate HBV addressing an urgent need for a coordinated approach to advancing HBV cure worldwide, such as those approaches established in the HIV field.
Keynote speaker, Enaam Oudih (Practice Manager, Multicultural Services, Manager BBV programs, Manager Multicultural Gambling Health Service, Relationships Australia, SA) presents community and social research as part of symposia titled Communities responding to hepatitis B: barriers, enablers and experiences.
Hear from speakers presenting clinical improvement outcomes for HBV antiviral therapy, including: Concordance between Missed Days of Hepatitis B Virus Anti-Viral Therapy and Virological Breakthrough with Suzanne Sheppard-Law (Senior Research Fellow, University of Technology Sydney/Sydney Children's Hospital Network); and Yes We Can! Optimising Treatment And Management of Chronic Hepatitis B Based on a Disease Registry with Ximena Masgoret (Research Assistant, Cancer Council NSW).
Models of improving public health access to testing and care are explored, including: Using a Knowledge Translation Approach to Increase Testing of Patients at Risk of Hepatitis B in a Primary Health Setting with Jacqui Richmond (Research Fellow / Clinical Nurse Consultant, La Trobe University / Melbourne Health); and Responding To Notifications of Unspecified Hepatitis B and C in Victoria with Nicole Romero (Epidemiologist, WHO Collaborating Centre for Viral Hepatitis, The Doherty Institute).
Listen to different approaches to community engagement among different population groups: "You Know In the Community When They Heard of Something and Then You Can't Even Be With Them": Lived Experiences of Chronic Hepatitis B among South Sudanese in Australia with William Mude (PhD Candidate, Australian Research Centre for Sex, Health and Society; La Trobe University); and Deadly Grandmothers; Proper Way Partnerships, Supporting Elders Working with Young People in Community with Jodie Walton (BBV & STI Education Project Officer, Hepatitis Queensland).
Go back to the top of the page
Acclaimed keynote speaker, Dr Professor Ed Gane (Deputy Director of New Zealand Liver Transplant Unit, Auckland City Hospital) presents We have Perfectovir - do we need anything else?
Keynote speaker, Kate Seear (ARC DECRA Fellow and Senior Lecturer in Law, Monash University) considers some of the ways that criminal justice settings are implicated in transmission, through, for example, the lack of needle and syringe programs in prisons and remand centres, and other institutional and legal forces that impact upon people who inject drugs in her paper titled Hepatitis Transmission and Prevention: Exploring the Role that the Law Plays in Shaping Blood Borne Virus Epidemics.
Hear speakers share best practice examples of reaching out in the new era of hepatitis C Antiviral Therapy: Karen Chronister (Research Coordinator, Kirketon Road Centre) presents The Dog at my Daclatasvir: Real Life Experiences Delivering Direct Acting Antivirals to Marginalised, Homeless, and Active Drug Users; and Dr David Baker (General Practitioner, East Sydney Doctors) presents Curing Hepatitis C in General Practice: The First 60 Days.
Speakers present community and social research papers on theme of HCV: On the Road to Elimination, including: Advocacy for Universal Access to Hepatitis C Medicines with Helen Tyrrell (CEO, Hepatitis Australia); and Prevalence and Correlates of Hepatitis C among Attendees at New Zealand Needle Exchanges: Results of the 2013 Seroprevalence Survey with Geoff Noller (Director / Research Consultant, Substance Use and Policy Analysis).
Hear Zoe Dodd (co-founder and Program Coordinator, Toronto Community Hep C Program) sharing insights from the Candian perspective of The Future of Hep C Care for People Who Use Drugs: Lessons from a Community-Based, Harm Reduction, Client-Driven Program in Toronto, Canada.
Keynote speaker, Professor Greg Dore (Head, Kirby Institute, UNSW) presents The New HCV treatment Era in Australia: Early Lessons with the inclusion of data on uptake of medications since March 2016.
Basic Science symposia sessions explore understanding of HCV transmission, immunity and diagnosis, including: Trends of Hepatitis C Virus Epidemic in Australia and North America in 20th Century: Back Projections from Molecular Epidemiology with Chaturaka Rodrigo (PhD Student, School of Medical Sciences, UNSW); and Mehdi Rasoli Pirozyan (PhD Student, University of New South Wales) present Commitment to CD8+ T Cell Exhaustion and Loss of Memory T Cell Potential Develops during Primary Chronic HCV Infection.
Make sure you stay for the closing plenary panel discussion weighing up whether the HBV and HCV elimination targets are realistic, with comparisons between Australia and New Zealand to be covered.
Go back to the top of the page
A series of complimentary satellite symposia sessions are also offered:
Curing HCV: Leave no Patient Behind (AbbVie Breakfast Satellite Symposium) addresses real world case studies and some of the challenges of how the new all-oral direct acting antivirals (despite revolutionising the treatment of hepatitis C in Australia) have presented challenges persisting with certain patient types and non-traditional treatment settings.
Hepatitis C - Effective Treatment For Everyone, Everywhere is an innovative, cutting-edge meeting that aims to explore optimal models for delivering care to people from diverse backgrounds and settings. Register for these sessions held prior to the conference on Wednesday 28 and Thursday 29 September.
Go back to the top of the page